Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Vision 2020 measures University of New Mexico's success by health of its state.

Kaufman A, Roth PB, Larson RS, Ridenour N, Welage LS, Romero-Leggott V, Nkouaga C, Armitage K, McKinney KL.

Am J Prev Med. 2015 Jan;48(1):108-15. doi: 10.1016/j.amepre.2014.08.001. Epub 2014 Nov 6.

PMID:
25441236
2.

Preparing clinical pharmacy scientists for careers in clinical/translational research: can we meet the challenge?: ACCP Research Affairs Committee Commentary.

Parker RB, Ellingrod V, DiPiro JT, Bauman JL, Blouin RA, Welage LS.

Pharmacotherapy. 2013 Dec;33(12):e337-46. doi: 10.1002/phar.1348. Epub 2013 Sep 30.

PMID:
24114730
3.

Building a multi-institutional community of practice to foster assessment.

Janke KK, Seaba HH, Welage LS, Scott SA, Rabi SM, Kelley KA, Mason HL.

Am J Pharm Educ. 2012 May 10;76(4):58. doi: 10.5688/ajpe76458.

4.

Does body weight impact the efficacy of vasopressin therapy in the management of septic shock?

Miller JT, Welage LS, Kraft MD, Alaniz C.

J Crit Care. 2012 Jun;27(3):289-93. doi: 10.1016/j.jcrc.2011.06.018. Epub 2011 Aug 19.

PMID:
21855282
5.

Cardiovascular risk among university students from developed and developing nations.

Bleske BE, Erickson SR, Fahoum S, Devarakonda KR, Welage LS, Koudmani M, Pantham N, Edwin SB, Devarakonda S, Shea MJ, Martha S, Khalidi N.

Open Cardiovasc Med J. 2011;5:117-22. doi: 10.2174/1874192401105010117. Epub 2011 May 13.

6.

High-dose PPIs in patients with variceal hemorrhage.

Alaniz C, Mohammad RA, Welage LS.

Arch Intern Med. 2010 Oct 11;170(18):1698. doi: 10.1001/archinternmed.2010.358. No abstract available.

PMID:
20937934
7.

The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics.

Stout SM, Nielsen J, Bleske BE, Shea M, Brook R, Kerber K, Welage LS.

J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):373-9. doi: 10.1177/1074248410372926. Epub 2010 Aug 12.

8.

Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.

Stout SM, Nielsen J, Welage LS, Shea M, Brook R, Kerber K, Bleske BE.

J Clin Pharmacol. 2011 Mar;51(3):389-96. doi: 10.1177/0091270010365559. Epub 2010 Apr 16.

9.

The role of dual-degree programs in colleges and schools of pharmacy: the report of the 2008-09 Research and Graduate Affairs Committee.

Crismon ML, Albright FS, Canney DJ, Das NG, Mehanna AS, Welage LS, Wu-Pong S, Miller KW.

Am J Pharm Educ. 2009;73 Suppl:S6. No abstract available.

10.

Effect of a Web-based continuing-education program on pharmacist learning.

Sweet BV, Welage LS, Johnston JP.

Am J Health Syst Pharm. 2009 Nov 1;66(21):1902-3. doi: 10.2146/ajhp080658. No abstract available.

PMID:
19850780
11.

Key articles and guidelines relative to intensive care unit pharmacotherapy: 2009 update.

Erstad BL, Brophy GM, Martin SJ, Haas CE, Devlin JW, Welage LS, Dager WE.

Pharmacotherapy. 2009 Oct;29(10):1228-69. doi: 10.1592/phco.29.10.1228.

12.

Intestinal dipeptide absorption is preserved during thermal injury and cytokine treatment.

Foster DR, Gonzales JP, Amidon GL, Welage LS.

JPEN J Parenter Enteral Nutr. 2009 Sep-Oct;33(5):520-8. doi: 10.1177/0148607109333002. Epub 2009 May 14.

13.

Continuous infusion of pantoprazole with octreotide does not improve management of variceal hemorrhage.

Alaniz C, Mohammad RA, Welage LS.

Pharmacotherapy. 2009 Mar;29(3):248-54. doi: 10.1592/phco.29.3.248.

14.

Lack of interaction between the peptidomimetic substrates captopril and cephradine.

Foster DR, Yee S, Bleske BE, Carver PL, Shea MJ, Menon SS, Ramachandran C, Welage LS, Amidon GL.

J Clin Pharmacol. 2009 Mar;49(3):360-7. doi: 10.1177/0091270008329554.

15.

Interferon-gamma increases expression of the di/tri-peptide transporter, h-PEPT1, and dipeptide transport in cultured human intestinal monolayers.

Foster DR, Landowski CP, Zheng X, Amidon GL, Welage LS.

Pharmacol Res. 2009 Mar;59(3):215-20. doi: 10.1016/j.phrs.2008.11.001. Epub 2008 Nov 25.

PMID:
19084598
16.

Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans.

Higaki K, Choe SY, Löbenberg R, Welage LS, Amidon GL.

Eur J Pharm Biopharm. 2008 Sep;70(1):313-25. doi: 10.1016/j.ejpb.2008.02.022. Epub 2008 Mar 7.

PMID:
18434110
17.

Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.

Devlin JW, Welage LS, Olsen KM.

Ann Pharmacother. 2005 Nov;39(11):1844-51. Epub 2005 Oct 4. Review.

PMID:
16204393
18.

Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations.

Devlin JW, Welage LS, Olsen KM.

Ann Pharmacother. 2005 Oct;39(10):1667-77. Epub 2005 Aug 23. Review.

PMID:
16118266
19.

Key articles and guidelines relative to intensive care unit pharmacology--2004.

Erstad BL, Martin SJ, Brophy GM, Haas CE, Jacobi J, Welage LS, Thomas MC.

Pharmacotherapy. 2005 Apr;25(4):585-610.

PMID:
15977919
20.

Overview of pharmacologic agents for acid suppression in critically ill patients.

Welage LS.

Am J Health Syst Pharm. 2005 May 15;62(10 Suppl 2):S4-S10. Review.

PMID:
15905600
21.

Review article: diagnosis and management of night-time reflux.

McGuigan JE, Belafsky PC, Fromer L, McCarthy D, Nostrant T, Postma GN, Welage LS, Wolfe MM.

Aliment Pharmacol Ther. 2004 Dec;20 Suppl 9:57-72. Review.

22.

Prevention of stress ulceration: current trends in critical care.

Daley RJ, Rebuck JA, Welage LS, Rogers FB.

Crit Care Med. 2004 Oct;32(10):2008-13.

PMID:
15483408
23.

The cost-effectiveness of proton pump inhibitors for bleeding peptic ulcers: The unanswered questions.

Devlin JW, Welage LS.

Crit Care Med. 2004 Jun;32(6):1415-6. No abstract available.

PMID:
15187531
24.

The effects of thermal injury on transcellular permeability and intestinal P-glycoprotein in rats.

Neudeck BL, Foster DR, Li LY, Gonzales JP, Welage LS.

Burns. 2003 Dec;29(8):803-9.

PMID:
14636755
25.

Pharmacologic properties of proton pump inhibitors.

Welage LS.

Pharmacotherapy. 2003 Oct;23(10 Pt 2):74S-80S. Review.

26.

Pharmacologic features of proton pump inhibitors and their potential relevance to clinical practice.

Welage LS.

Gastroenterol Clin North Am. 2003 Sep;32(3 Suppl):S25-35. Review.

PMID:
14556433
27.
28.

Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells.

Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL.

Pharm Res. 2003 May;20(5):749-56.

29.

Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters.

Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, Ramachandran C, Amidon GL.

J Pharmacol Exp Ther. 2003 Aug;306(2):778-86. Epub 2003 May 15.

PMID:
12750437
30.

Strategies to optimize drotrecogin alfa (activated) use: guidelines and therapeutic controversies.

Cohen H, Welage LS.

Pharmacotherapy. 2002 Dec;22(12 Pt 2):223S-235S. Review.

31.

Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs.

Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL.

Pharm Res. 2002 Oct;19(10):1400-16.

32.

Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility.

Takamatsu N, Welage LS, Hayashi Y, Yamamoto R, Barnett JL, Shah VP, Lesko LJ, Ramachandran C, Amidon GL.

Eur J Pharm Biopharm. 2002 Jan;53(1):37-47. Erratum in: Eur J Pharm Biopharm. 2002 Sep;54(2):255.

PMID:
11777751
33.

Proton pump inhibitors and gastric acid secretion.

Wolfe MM, Welage LS, Sachs G.

Am J Gastroenterol. 2001 Dec;96(12):3467-8. No abstract available.

34.

Drug product selection: legal issues.

Christensen TP, Kirking DM, Ascione FJ, Welage LS, Gaither CA.

J Am Pharm Assoc (Wash). 2001 Nov-Dec;41(6):868-74. Review.

PMID:
11765112
35.

Understanding the scientific issues embedded in the generic drug approval process.

Welage LS, Kirking DM, Ascione FJ, Gaither CA.

J Am Pharm Assoc (Wash). 2001 Nov-Dec;41(6):856-67. Review.

PMID:
11765111
36.

Novel method to assess gastric emptying in humans: the Pellet Gastric Emptying Test.

Choe SY, Neudeck BL, Welage LS, Amidon GE, Barnett JL, Amidon GL.

Eur J Pharm Sci. 2001 Dec;14(4):347-53.

PMID:
11684410
37.

Economics and structure of the generic pharmaceutical industry.

Kirking DM, Ascione FJ, Gaither CA, Welage LS.

J Am Pharm Assoc (Wash). 2001 Jul-Aug;41(4):578-84. Review.

PMID:
11486984
38.

Historical overview of generic medication policy.

Ascione FJ, Kirking DM, Gaither CA, Welage LS.

J Am Pharm Assoc (Wash). 2001 Jul-Aug;41(4):567-77.

PMID:
11486983
39.

Human jejunal permeability of two polar drugs: cimetidine and ranitidine.

Takamatsu N, Kim ON, Welage LS, Idkaidek NM, Hayashi Y, Barnett J, Yamamoto R, Lipka E, Lennernäs H, Hussain A, Lesko L, Amidon GL.

Pharm Res. 2001 Jun;18(6):742-4.

40.

Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.

Welage LS, Berardi RR.

J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):52-62; quiz 121-3. Review.

PMID:
10665250
41.

Proton-pump inhibitors in acid-related diseases.

Berardi RR, Welage LS.

Am J Health Syst Pharm. 1998 Nov 1;55(21):2289-98. Review. No abstract available.

PMID:
9825880
42.

Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure.

Bleske BE, Welage LS, Kramer WG, Nicklas JM.

J Clin Pharmacol. 1998 Aug;38(8):708-14.

43.

Determination of fluoxetine and norfluoxetine concentrations in cadaveric allograft skin.

Neudeck BL, Taddonio TE, Garner WL, Welage LS.

Pharmacotherapy. 1998 Jul-Aug;18(4):851-5.

44.

Drug marker absorption in relation to pellet size, gastric motility and viscous meals in humans.

Rhie JK, Hayashi Y, Welage LS, Frens J, Wald RJ, Barnett JL, Amidon GE, Putcha L, Amidon GL.

Pharm Res. 1998 Feb;15(2):233-8.

45.

Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion.

Takamatsu N, Welage LS, Idkaidek NM, Liu DY, Lee PI, Hayashi Y, Rhie JK, Lennernäs H, Barnett JL, Shah VP, Lesko L, Amidon GL.

Pharm Res. 1997 Sep;14(9):1127-32.

46.

Alterations in gastric acidity in patients infected with human immunodeficiency virus.

Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA.

Clin Infect Dis. 1995 Dec;21(6):1431-8.

PMID:
8749628
47.

Variations in prothrombin time and international normalized ratio over 24 hours in warfarin-treated patients.

Bleske BE, Welage LS, Warren EW, Brown MB, Shea MJ.

Pharmacotherapy. 1995 Nov-Dec;15(6):709-12.

PMID:
8602377
48.

Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics.

Welage LS, Mason NA, Hoffman EJ, Odeh RM, Dombrouski J, Patel JA, Swartz RD.

J Am Soc Nephrol. 1995 Oct;6(4):1284-90.

49.

A Double-Blind, Randomized Comparison of Aztreonam Plus Clindamycin with Tobramycin Plus Clindamycin in Abdominal Infections.

Ballow CH, Wels PB, Welage LS, Walczak P, Williams JS, Schentag JJ.

Am J Ther. 1995 Jun;2(6):373-377.

PMID:
11850680
50.

The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans.

Bleske BE, Welage LS, Rose S, Amidon GL, Shea MJ.

J Clin Pharmacol. 1995 Apr;35(4):374-8.

Supplemental Content

Loading ...
Support Center